BioCentury
ARTICLE | Clinical News

ASN-002: Interim Ph I/IIa data

December 2, 2016 5:12 PM UTC

Interim data from 9 patients with nodular BCC in an open-label, Australian Phase I/IIa trial showed that once-weekly intratumoral ASN-002 for 3 weeks led to an overall response rate (ORR) of 100%, com...